Yes, insulin glargine is definitively a long-acting basal insulin.
Insulin glargine is a long-acting human insulin analog specifically designed to provide basal insulin coverage for 24 hours with once-daily dosing 1. This is confirmed by both FDA labeling and current clinical guidelines.
Pharmacologic Classification
Insulin glargine is classified as a long-acting basal insulin in the 2025 American Diabetes Association Standards of Care 2. The FDA drug label explicitly describes it as "a long-acting human insulin analog" produced through recombinant DNA technology 1.
Key Pharmacokinetic Properties
The molecular structure of insulin glargine distinguishes it from human insulin through two modifications:
- Asparagine at position A21 is replaced by glycine
- Two arginine molecules are added to the C-terminus of the B-chain 1
These structural changes result in:
- Duration of action: approximately 24 hours
- Flat, peakless time-action profile (minimal peak effect compared to intermediate-acting insulins like NPH)
- Once-daily dosing capability 3, 4
Clinical Context
Insulin glargine revolutionized diabetes management when introduced in 2000 by providing true basal insulin replacement 3. It replaced the era of twice-daily intermediate-acting insulins (NPH, lente) that required more frequent dosing and had pronounced peaks associated with higher hypoglycemia risk 3, 4.
Available Formulations
Multiple concentrations exist with varying pharmacokinetic profiles:
- U-100 glargine: Standard formulation
- U-300 glargine: Three times more concentrated with longer duration of action than U-100, though modestly lower efficacy per unit administered 2
Important Clinical Distinction
A common pitfall: Do not confuse insulin glargine with rapid-acting or intermediate-acting insulins. Glargine provides basal coverage only and does not address prandial (mealtime) glucose excursions 4, 5. Patients typically require additional rapid-acting insulin at meals for comprehensive glycemic control 2.